STAT

Opinion: DNA donors must demand stronger protection for genetic privacy

Thinking about doing one of those DNA sequencing kits or participating in @NIH's All of Us? Think twice — your genetic privacy isn't protected as well as it should be.
Source: GEORGES GOBET/AFP/Getty Images

The National Institutes of Health wants your DNA, and the DNA of 1 million other Americans, for an ambitious project called All of Us. Its goal — to “uncover paths toward delivering precision medicine” — is a good one. But until it can safeguard participants’ genetic privacy, you should decline the invitation to join unless you fully understand and accept the risks.

DNA databases like All of Us could provide valuable medical breakthroughs such as identifying new disease risk factors and potential drug targets. But these benefits could come with a high price: increased risk to individuals’ genetic data privacy, something that current U.S. laws do not adequately protect.

This month, it was throwing open the doors to enrollment in” by using an online DNA database called . In mid-May, the same database was used to help solve a committed in Washington state in 1987. Earlier this year, the broke, showing that a data analytics firm collected private information on up to 87 million Facebook users. Notwithstanding the benefits to law enforcement, these and other revelations are eroding public trust in social media and genealogy websites like 23andMe and Ancestry.com. Without trust, it will be difficult for programs like the All of Us initiative to succeed.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks